Latest updates on atopic dermatitis
References
Ardern-Jones MR, Flohr C, Reynolds NJ, Holden CA. Atopic Eczema. In: Griffiths CEM, Barker J, Bleiker T, Charmers R, Creamers D, Eds. Rook’s Textbook of Dermatology. 9th Edn. Oxford: Wiley-Blackwell; 2016. p 41.33-41.34.
Leung TN, Hon KL. Eczema therapeutics in children: what do the clinical trials say? Hong Kong Med J. 2015;21: 251–60.
Paton DM. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis. Drugs Today. 2017;53:239-45.
Bissionnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175:902-11.
Saporito RC, Cohen DJ. Apremilast use for moderate-to-severe atopic dermatitis in pediatric patients. Case Rep Dermatol. 2016;8:179-84.
10Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76:736-43.
Tsianakas A, Luger TA, Radin A. Dupilumab treatment improves quality of life in adult patients with moderate to severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Br J Dermatol. 2017 (ahead of publication).
Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Exp Rev Clin Immunol. 2017;13:425-37.
Vakharia PP, Silverberg JI. Monoclonal antibodies for atopic dermatitis: Progress and potential. BioDrugs. 2017;31:409-22.
Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: End of the drought? J Allergy Clin Immunol. 2017;140:633-43.
